Doxorubicin-carrying Liposomes

Author: admin     Date: 3 9 月, 2024

Characterization of Doxorubicin-Carrying Doxoves

In nanomedicine development, nanoparticles are utilized as carriers to deliver payloads such as therapeutic agents. Therefore, the simultaneous detection of both nanoparticles and their cargos is desirable. Doxil (doxorubicin-carrying liposomes) is the first FDA-approved nanomedicine (1995), and DLS and cryo-TEM are the two most commonly used methods for size analysis. While DLS is not suitable for heterogeneous samples, the three-dimensional (3D) reconstruction of cryo-TEM usually takes 2-3 days.

Learn More

Multiparameter Quantification of Liposomes

A liposome is a tiny vesicle made from materials similar to a cell membrane. Drug-encapsulated liposomes have been considered the most clinically acceptable drug delivery systems. In this study, the Flow NanoAnalyzer was used to simultaneously detect the side-scatter and fluorescence signals generated by individual liposome particles at a speed of up to 10,000 nanoparticles/min. To address the size dependence of the refractive index of liposomes, different sizes of doxorubicin-loaded liposomes were fabricated and characterized to serve as calibration standards for measuring both particle size and drug content. This method provides a highly practical platform for the characterization of liposome vesicles.

Learn More

Quantification of Available Ligand Density on the Surface of Targeted Liposomal Nanomedicines

Author: admin     Date: 3 9 月, 2024

Active targeting has been hailed as one of the most promising strategies to further enhance the therapeutic efficacy of liposomal nanomedicines. Owing to the critical role of ligand density in mediating cellular uptake and the intrinsic heterogeneity of liposomal formulations, precise quantification of the surface ligand density on a single-particle basis is of fundamental importance. In this work, we report a method to simultaneously measure the particle size and the number of ligands on the same liposomal nanoparticles by nanoflow cytometry. From this the ligand density for each individual liposome could be determined. The correlation between the available ligand density and cell targeting capability was assessed in quantitatively for liposomes modified with three different targeting moieties. The optimal ligand density was determined to be 0.5–2.0, 0.7, and 0.2 ligands per 100 nm^2 for folate-, transferrin-, and HER2-antibody-conjugated liposomes, respectively. These optimal values agreed well with the spike density of the natural counterparts, viruses. The as-developed approach can be applied to a wide range of active-targeting nanocarriers. The correlation between the available ligand density and cell targeting capability was assessed in a quantitative perspective for liposomes modified with three different targeting moieties.

                    Figure 1. Nano-flow cytometry (nFCM) analysis                    Figure 2. Measurement and calculation of the ligand 

       of the surface folate receptor expression                           density by nano-flow cytomstry (nFCM)

The optimal ligand density was determined to be 0.5–2.0, 0.7, and 0.2 ligands per 100 nm^2 for folate-, transferrin-, and HER2-antibody-conjugated liposomes, respectively. These optimal values agreed well with the spike density of the natural counterparts, viruses. The as-developed approach is generally applicable to a wide range of active-targeting nanocarriers.

ACS Nano, 2022, 16(4), 6886-6897.